<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low course doses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (1.9 +/- 0.2 g) were given to postsplenectomy patients with grave <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (GAA) </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 27 patients aged 14-42 years were treated, 27 control GAA patients did not receive <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> therapy was controlled by T-lymphocyte functional activity assessed in active rosette formation test with levamisole in vitro </plain></SENT>
<SENT sid="3" pm="."><plain>19 (70.3%) patients were treated twice </plain></SENT>
<SENT sid="4" pm="."><plain>The remission was achieved in 22 patients (81.5%), partial response was in 1 patient (3.7%), 4 patients died (14.8%) </plain></SENT>
<SENT sid="5" pm="."><plain>In control subjects the remission was recorded only in 4 subjects, 23 patients died 3 to 12 months after splenectomy </plain></SENT>
<SENT sid="6" pm="."><plain>It is evident that low-dose courses of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> are highly effective in case of control over immunological activity of the <z:mpath ids='MPATH_596'>pathological process</z:mpath> </plain></SENT>
</text></document>